CancerCare's 2016 Patient Access and Engagement Report underscores barriers for patient access to care, as well as communication gaps with care providers, both of which have a significant impact on patient outcomes.
CancerCare, an organization that provides information and support services to cancer patients, has commissioned a report that presents the physical, financial, practical, and informational needs of more than 3000 cancer patients. The 2016 Patient Access and Engagement Report has tried to reflect barriers for patient access to care, as well as communication gaps with care providers, both of which have a significant impact on patient outcomes.
The advisory board that helped develop the report included healthcare providers and leaders within CancerCare. Patients who participated in the survey represented diverse ethnicity, income, education, geography, age, insurance, cancer type, and treatment stage. The following are some of the findings of the study:
Understanding Diagnosis
Treatment Planning
Communication With Care Team
Financial and Insurance Issues
Symptoms, Side Effects, and Quality of Life
Survivorship
“Cancer takes its toll in many ways, some of which last for years and cause debilitating distress for patients and families,” Patricia J. Goldsmith, CEO of CancerCare, said in a statement. “This report, reflecting the input of thousands of patients, sheds light on the important issues affecting patients’ lives during and beyond a cancer diagnosis.”
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Housing Assistance May Help Renters With Cancer Better Withstand Medical Financial Strain
August 28th 2025Housing assistance significantly reduces medical financial hardship for renters with a history of cancer, enhancing their financial security and access to care amid rising health costs.
Read More
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More